Prevents deep vein thrombosis (DVT). Sold as Arixtra. Every FDA application for this active ingredient: 1 branded and 6 generic.
As of Nov 16, 2026, FDA lists 7 applications for Fondaparinux Sodium (sold as Arixtra), first approved Dec 7, 2001, with 5 new uses approved and 0 published complete response letters.
| Fondaparinux Sodium | Part D | $14.3M | -3% | 2,798 |
| Arixtra | Part D | $152K | -28% | 0 |
| Arixtra | Part B | $1K | -76% | 20 |
| Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis · Argyrios Tzouvelekis | Phase 3 | Recruiting | Dec 23, 2025 |
| Hip Fracture Surgery Arterial and Venous Thrombotic Events PreventionHip Fracture Surgery, Cardiovascular Prevention · McMaster University | Phase 3 | Not yet recruiting | Nov 14, 2025 |
| Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial InfarctionNSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI), Acute Myocardial Infarction (AMI) · University of Aarhus | Phase 4 | Recruiting | Nov 29, 2024 |
| Thromboprophylaxis in Lower Limb ImmobilisationThrombosis, Injury Leg · Queen Mary University of London | Phase 3 | Recruiting | Apr 17, 2024 |
| START-Register: Survey on Anticoagulated Patients RegisterAtrial Fibrillation, Venous Thromboembolism · GUALTIERO PALARETI | — | Recruiting | Aug 19, 2014 |
| Dec 7, 2001 | ArixtraNDA 21345 · New molecular entity | Mylan Ireland Ltd | 17 | Marketed |
| Jul 11, 2011 | Fondaparinux SodiumANDA 91316 | Dr Reddys Labs Ltd | 2 | Marketed |
| Dec 26, 2017 | Fondaparinux SodiumANDA 206918 | Eugia Pharma | 0 | Marketed |
| May 15, 2018 | Fondaparinux SodiumANDA 206812 | Hengrui Pharma | 0 | Discontinued |
| Nov 14, 2018 | Fondaparinux SodiumANDA 208615 | Scinopharm Taiwan | 1 | Marketed |
| Aug 19, 2024 | Fondaparinux SodiumANDA 216493 | Hangzhou Zhongmei | 0 | Discontinued |
| Dec 18, 2024 | Fondaparinux SodiumANDA 218312 | Brightgene | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA